<DOC>
	<DOCNO>NCT00378092</DOCNO>
	<brief_summary>The purpose study evaluate outcome medication discontinuation , safety effectiveness re-initiating risperidone long act injection ( RLAI ) case relapse ( return medical problem ) schizophrenia ( psychiatric disorder symptom emotional instability , detachment reality , often delusion hallucination , withdrawal self ) study observation period 36 month .</brief_summary>
	<brief_title>A Follow-Up Study Schizophrenic Participants Following Treatment Discontinuation After Remission From First Psychotic Episode</brief_title>
	<detailed_description>This open-label ( people know identity intervention ) , prospective ( study follow participant forward time ) , single-arm , single-center study assess consequence treatment discontinuation evaluate clinical response re-initiation risperidone case relapse . The study consist 2 period : Period 1 Period 2 . Participants RLAI 24 month remission ( medical problem get good go away least ) state enter Period 1 . In Period 1 : RLAI taper discontinued period 6 week . Participants regularly carefully followed-up first disease relapse maximum 36 month . In case relapse ( i.e. , participant experience similar symptom experience time study entry previous Study RIS-PSY-301 ) , participant transfer Period 1 Period 2 . In Period 2 , participant re-start medication RLAI ( 25 milligram [ mg ] , 37.5 mg , 50 mg [ maximum ] ) simultaneously start oral ( take mouth ) risperidone ( 1 mg , 2 mg , 3 mg ) . Doses adjusted Investigator 's discretion . Oral Risperidone give first 3 week RLAI injection become effective . RLAI injection continue maximum 24 month . Participants followed-up ( new ) relapse treatment stop , maximum 24 month . The total duration study 36 month include 16 visit . Assessments perform every 2 month first year every 3 month follow 24 month period . Time relapse rate relapse measure primary outcome Period 1 degree clinical improvement measure Positive And Negative Syndrome Scale ( PANSS ) total score schizophrenia . Time response re-exposure treatment RLAI measure primary outcome Period 2 . Participants ' safety monitor throughout study .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Risperidone</mesh_term>
	<criteria>Participants complete 24 month RISPSY301 study Surgically sterile female participant practice effective method birth control entry throughout study ; must show negative urine serum pregnancy test baseline study entry Participants sign informed consent document Participants require treatment mood stabilizer antidepressant study entry Participants evidence alcohol drug abuse dependence ( except nicotine caffeine dependence ) accord Diagnostic Statistical Manual Mental Disorders ( DSMIV ) criterion diagnose last month entry Participants history severe drug allergy , drug hypersensitivity , neuroleptic malignant ( cancerous ) syndrome Participants know hypersensitivity risperidone Participants acute risk suicide study entry history suicidal attempt ( )</criteria>
	<gender>All</gender>
	<minimum_age>17 Years</minimum_age>
	<maximum_age>47 Years</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>Risperidone</keyword>
	<keyword>Risperdal consta</keyword>
</DOC>